Clinical Research Trial for Prostate Cancer  
(Gene Vaccine Clinical Trial for Men with Newly Diagnosed Prostate Cancer Who Are Candidates for Active Surveillance)

Principal Investigator: Mitchell H Sokoloff  
Co-Investigators: Jennifer Yates MD and Terence R Flotte MD

Place: University of Massachusetts Medical Center (one of many sites) in collaboration with Advantagene Inc.

Departments: Urology and Gene Therapy,

Purpose: Evaluate whether addition of a research product AdV-tk plus valacyclovir improves the clinical outcome and quality of life for patients undergoing active surveillance.

Research Product: AdV-tk and valacyclovir uses gene transfer technology to deliver a gene to a tumor to kill tumor cells

Administration:
• Randomized to test arm or control 2:1 (2/3 of patients receiving the research product)  
• AdV-tk or placebo is delivered to the prostate via Transrectal ultrasound-guided injections on 2 occasions.

To be eligible, volunteers must be:
• 18 years of age and older  
• Currently undergoing active surveillance and able to tolerate transrectal ultrasound guided injections and biopsies

Involvement in the study requires:
• about 8 visits over a 1 year period with contact for 5 years annually to evaluate transition to radical treatment.

For further information contact: Margaret Humphries, RN at (508) 856-5711 or Margaret.Humphries@umassmed.edu  
www.clinicaltrials.com/